ISRCTN75434529进行中（未招募）1 期
A single-center, adaptive, repeated dose, phase I study to investigate the pharmacodynamics of RO7269162 following oral administration in presymptomatic carriers and in non-carriers of a genetic mutation from the same kindred in autosomal-dominant Alzheimer’s Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. 18 to 25 years of age inclusive
- •2. Membership in gene mutation carrier kindred. Gene mutation carrier or non-carrier status will have been confirmed prior to or during the screening period
- •3. Body mass index (BMI) of 18-32 kilograms per metre square (kg/m²) inclusive
排除标准
- •1. Any clinically relevant finding, condition or disease detected during the medical interview/physical examination at screening or Day -1.
- •2. History or evidence of any medical condition capable of significantly altering the absorption, metabolism, or elimination of drugs, including surgical history affecting gastric motility or altering the gastrointestinal tract.
- •3. History of convulsions
- •4. Participants who, in the investigator`s judgment, pose a suicidal or homicidal risk
- •5. Vaccination within 6 weeks prior to Day 1 including influenza and/or SARS-CoV-2/COVID-19 vaccination.
- •6. Positive result on human immunodeficiency virus 1 (HIV1) and HIV2, hepatitis C virus (HCV) or hepatitis B (HBV).
- •7. Participants who test positive for acute respiratory syndrome coronavirus 2 (SARSCoV-2) on admission to the study site
研究者
相似试验
未知
1 期
A Single-center, Single- and Multiple-Dose Phase 1 Study to Evaluate the Safety and Pharmacokinetics of TAK-114 in Healthy Adult Japanese and Caucasian Male SubjectsJPRN-jRCT2080222640TAKEDA PHARMACEUTICAL COMPANY LTD.82
已完成
1 期
A Phase 1, Single-Center, Dose-Escalation and Fixed-Dose Crossover, Cohort Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF329 vs oral hydromorphone hydrochloride (HCl) in Healthy SubjectsACTRN12610000721000PharmacoFore, Inc.80
已完成
1 期
A single center, open-label, repeated dose, Phase I study in healthy subjects to assess the safety, tolerability, pharmacokinetics and the effect on mobilization of hematopoietic stem cells of NOX-A12 alone and in combination with filgrastim.MedDRA - LLT 10053943 (Hämatopoietische Stammzellmobilisierung/ Hematopoietic stem cell mobilization)MedDRA - LLT 10029547 (Non-Hodgkin's Lymphom / Non-Hodgkin's Lymphoma)MedDRA - LLT 10028233 (Multiples Myelom ohne erwähnte Remession / Multiple myeloma without mention of remission)C81Hodgkin lymphomaDRKS00003104OXXON Pharma AG12
尚未招募
不适用
A phase 1, single centre, single dose, double-blind, double-dummy, four-way crossover, placebo-controlled, randomized study to investigate the effects of AZD7325 on sedation, cognition and EEG in comparison with lorazepam in healthy male volunteers.anxiety disorders10002861anxietyNL-OMON32334Astra Zeneca16
已完成
1 期
A Phase 1, Single-Center, Dose-Ranging, Multi-Treatment Study to Determine the Safety and Pharmacokinetics of Single Oral Dose Combinations of PF329 and Nafamostat Mesilate in Healthy SubjectsACTRN12612000880842Signature Therapeutics, Inc.14